thebench.bio #1 Ecosystem for the Bio-Tech Industry

Industry Daily Summary

Industry Daily Summary: What Happened on November 17, 2026

J&J agrees to pay $2.2 billion upfront for Ollin’s eye drugs

Lilly added a mutant-calreticulin antibody to its pipeline, while Seawolf paired $100 million in funding with a Sanofi licensing deal.

  • Updated
  • Read from 7 articles, 4 publications

Today in brief

Johnson & Johnson will acquire Ollin Biosciences for $2.2 billion upfront, gaining a late-stage retinal drug and another antibody program.12 Eli Lilly will acquire Calytrix Bio in a deal worth as much as $1.5 billion, most of it contingent on clinical and regulatory milestones.3

Seawolf Therapeutics emerged from stealth with $100 million in financing and a Sanofi partnership that could generate as much as $1.2 billion in milestone payments.4

J&J adds Ollin’s late-stage retinal drug

Johnson & Johnson agreed to acquire Ollin Biosciences for $2.2 billion upfront, plus as much as $1.125 billion in regulatory and commercial milestones.12 The deal includes OLN324, a bispecific antibody in Phase III development for wet age-related macular degeneration and diabetic macular edema.15

OLN324 targets VEGF and Ang2, the same pathways targeted by Roche’s Vabysmo.12 Ollin reported that, in a Phase 1b comparison, OLN324 produced faster and greater structural changes and numerically greater vision improvement than Vabysmo at 20 weeks.2 The results come from an early-stage study. J&J will take responsibility for the pivotal trials.2

Blackstone Life Sciences will provide as much as $750 million for Phase III development in return for potential milestones and royalties.12 The acquisition also includes OLN102, an investigational antibody for thyroid eye disorder.2 The companies expect the deal to close by year-end.2

Lilly buys Calytrix for a mutant-calreticulin antibody

Eli Lilly agreed to acquire Calytrix Bio in a transaction worth as much as $1.5 billion, including an upfront payment and further payments tied to clinical and regulatory milestones.3 Calytrix’s investigational antibody is designed to target Type 1 and Type 2 mutant calreticulin on tumor cells.3

Calytrix says the approach is intended to remove mutant cells while sparing healthy tissue and normal blood-cell production.3 The company is developing the program for essential thrombocythemia and myelofibrosis, two blood disorders.3 J.P. Morgan Life Sciences Private Capital established Calytrix in 2025.3

Seawolf pairs $100 million financing with Sanofi deal

Seawolf Therapeutics emerged from stealth with $100 million in seed and Series A financing and an exclusive licensing partnership with Sanofi.4 The collaboration will research treatments for bleeding disorders and other undisclosed indications.4 Milestone payments for research, development, and commercial progress could total as much as $1.2 billion, with royalties also possible for Seawolf.4

Seawolf’s TRIDENT platform uses lipid nanoparticles to carry DNA into cell nuclei, aiming to support production of a therapeutic protein.4 The company says its nonviral system may allow repeat dosing. Seawolf reported proof of concept in preclinical mouse and nonhuman-primate models.4 Seawolf is also advancing an internal program for metabolic diseases.4

Also worth knowing

  • Cellectis plans to cut as much as 70% of its workforce in 2026 and 2027 after ending two clinical-stage CAR-T programs, shifting resources to two preclinical gene-editing programs.6

  • AstraZeneca acquired Omniose, its US research partner, for an undisclosed amount to support preclinical vaccine programs against serious bacterial infections.6

  • More than 100 UK bio-based-industry stakeholders urged the government to back domestic manufacturing and commercialization, warning that research benefits could move overseas.7

Also published